8
Aug
2019

Novartis’ No-No, Bayer Buys BlueRock, and Job Switches Galore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings